Genomic Subtyping Could Guide Treatment Decisions for Bladder Cancer Data source: Bryant Furlow, Cancer Network Genomic subtyping of muscle-invasive bladder cancer could inform decisions on when best to use neoadjuvant cisplatin-based chemotherapy (NAC), according to a retrospective, non-randomized study presented (abstract 281) at the 2017 American Society of Clinical Oncology (ASCO) Genitourinary Cancers Symposium Different molecular muscle-invasive bladder cancer subtypes … Read More
In due time a new EUOG clinical trial to be launched
This new study with the name “Neo-adjuvant versus Adjuvant chemotherapy in Upper Tract Urothelial Carcinoma: A feasibility phase II randomized clinical trial (“URANUS”)” is an exploratory randomized study. Patients who have been diagnosed with cancer in the upper urinary tract and meet the inclusion criteria, will be treated by receiving 3 cycles of neo-adjuvant or 3 cycles of adjuvant chemotherapy. A … Read More
- Page 2 of 2
- 1
- 2